Skip to main content

Table 3 Individual outcome analysis according to treatment with pioglitazone and lobeglitazone

From: Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study

Outcome (number of case patients with the outcome)

Primary outcome (N = 20,869)

Stroke (N = 10,060)

Myocardial infarction (N = 951)

All-cause mortality (N = 9,858)

Thiazolidinedione treatment

    

 no thiazolidinedione

ref

ref

ref

ref

 Lobeglitazone

0.74 [0.61–0.90], p = 0.002

0.85 [0.68–1.08], p = 0.186

0.70 [0.33–1.47], p = 0.344

0.58 [0.39–0.86], p = 0.006

 Pioglitazone

0.71 [0.64–0.78], p < 0.001

0.78 [0.69–0.89], p < 0.001

0.71 [0.47–1.08], p = 0.111

0.60 [0.49–0.72], p < 0.001

  1. Data are adjusted odds ratios and [95% confidence intervals] obtained from multivariable conditional logistic regression analyses adjusted for the covariables described in Table 2 with the matched case-control dataset described in Table 1